Related Experiment Video
Updated: Apr 13, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Therapeutic Effectiveness of Screening for Multiple Endocrine Neoplasia Type 2A
Andreas Machens1, Henning Dralle1
1Department of General, Visceral, and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, D-06097 Halle (Saale), Germany.
Context:
Although technological progress revolutionized detection of genetic predisposition to medullary thyroid cancer (MTC), carriers of mutations of disparate risks may not have benefitted alike from screening.
Objective:
This investigation aimed at assessing the achievements of screening for multiple endocrine neoplasia type 2A (MEN 2A) in Germany and identifying current challenges.
Design:
This was a retrospective analysis comprising 455 carriers at risk of MEN 2A screened and operated between 1963 and 2014.
Setting:
The setting was tertiary surgical referral centers.
Patients:
Included were 175 carriers of American Thyroid Association (ATA) level C mutations (codon 634); 116 carriers of ATA level B mutations (codons 609, 611, 618, 620 and 630); and 164 carriers of ATA level A mutations (codons 768, 790, 791, 804 and 891).
Interventions:
The intervention was thyroidectomy.
Main Outcome Measures:
Main outcome measures were percentage of index patients among all carriers and percentage of MTC, node-positive MTC, and biochemical cure among non-index patients.
Results:
The percentage of index patients among all carriers fell from 50% (ATA level C) and 100% (ATA levels B and A) to 16, 29, and 31%, respectively. Among non-index patients, the percentage of MTC fell for ATA levels C and B but not for ATA level A mutations. The corresponding percentage of node-positive MTC declined since 1963 from 100 to 0% (ATA level C) and since 1995 from 67 to 33% (ATA level B) and from 11 to 10% (ATA level A), whereas biochemical cure increased from 0 to 100% since 1963 (ATA level C), and since 1995 from 71 to 78% (ATA level B) and from 95 to 100% (ATA level A).
Conclusions:
Screening efforts need to focus on sporadic-appearing MTC to deplete the pool of unrecognized carriers of ATA level B and A mutations and enable earlier pre-emptive thyroidectomy in their offspring.
